Archives: Episode

Check out this week’s Quadcast as we highlight hyperbaric oxygen for chronic RT side effects, optimal treatment for nasopharyngeal cancer, predictors of in-field failure in head and neck cancer, and more.

Check out this week’s QuadCast as we highlight the role of systemic therapy with SABR in oligometastatic disease, the role of immunotherapy in EGFR-mutated Stage III NSCLC, the role of mirtazepine in cancer-related anorexia, and more.

Check out this week’s QuadCast as we highlight if testosterone replacement therapy in men with Low T affects prostate cancer risk, the combination of pyrotinib + capecitabine + brain RT, the importance of dose to pulmonary veins in the development of A-fib, and more.

Check out this week’s QuadCast! We highlight results of potentially practice changing B-51, published results of the CURB trial for oligoprogressive lung & breast cancer, what to do with the rare radiation refractory plasmacytoma, and more.

Check out this week’s QuadCast as we highlight PACIFIC-2 using concurrent durvalumab in NSCLC, predictive MRI features for prostate cancer outcomes, the benefit of radiation in H&N Merkel cell carcinoma, and more!

Check out this week’s QuadCast as we highlight why radiation therapy is important in Hodgkin Lymphoma, the fact that invasive lobular carcinoma may be sneakily more aggressive than their ductal counterparts, and more!

Check out this week’s QuadCast as we highlight recent reporting from ESMO on best approach to potentially resectable pancreatic cancer, optimal timing of post-op radiosurgery for resected brain mets, the efficacy of dostarlimab on mismatch repair deficient tumors, and more.

Check out this week’s QuadCast as we highlight TNT with chemoradiation to reduce the need for surgery on the OPRA trial, the safety of a laparoscopic Whipple, the dangers of HER2-targeted agents during pregnancy, and more.

Check out this week’s QuadCast as we highlight the risk of using antibody drug conjugates with brain SRS, 5 fraction APBI on consecutive days, a better way to classify perineural invasion, and more.

Check out this week’s QuadCast as we highlight shorter duration trastuzumab for breast cancer, reduced length ADT in prostate cancer patients receiving brachy boost, head & neck location as a high risk factor in Merkel cell carcinoma, and more.